[go: up one dir, main page]

TN2009000213A1 - Combination - Google Patents

Combination

Info

Publication number
TN2009000213A1
TN2009000213A1 TNP2009000213A TN2009000213A TN2009000213A1 TN 2009000213 A1 TN2009000213 A1 TN 2009000213A1 TN P2009000213 A TNP2009000213 A TN P2009000213A TN 2009000213 A TN2009000213 A TN 2009000213A TN 2009000213 A1 TN2009000213 A1 TN 2009000213A1
Authority
TN
Tunisia
Prior art keywords
combination
relates
aml
mds
hdai
Prior art date
Application number
TNP2009000213A
Other languages
English (en)
Inventor
Peter Wisdom Atadja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39272127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000213(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000213A1 publication Critical patent/TN2009000213A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TNP2009000213A 2006-12-04 2009-05-29 Combination TN2009000213A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86838806P 2006-12-04 2006-12-04
PCT/US2007/024712 WO2008070011A2 (fr) 2006-12-04 2007-11-30 Combinaison

Publications (1)

Publication Number Publication Date
TN2009000213A1 true TN2009000213A1 (en) 2010-10-18

Family

ID=39272127

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000213A TN2009000213A1 (en) 2006-12-04 2009-05-29 Combination

Country Status (25)

Country Link
US (1) US8093220B2 (fr)
EP (1) EP2099451B1 (fr)
JP (3) JP5784274B2 (fr)
KR (1) KR101475538B1 (fr)
CN (1) CN101553223A (fr)
AR (1) AR064072A1 (fr)
AU (1) AU2007328281B2 (fr)
BR (1) BRPI0719746A2 (fr)
CA (1) CA2670741C (fr)
CL (1) CL2007003467A1 (fr)
EC (1) ECSP099483A (fr)
ES (1) ES2569477T3 (fr)
GT (1) GT200900148A (fr)
IL (1) IL198638A (fr)
MA (1) MA30982B1 (fr)
MX (1) MX2009005946A (fr)
MY (1) MY148893A (fr)
NO (1) NO20092473L (fr)
PE (1) PE20081303A1 (fr)
PL (1) PL2099451T3 (fr)
RU (1) RU2469717C2 (fr)
TN (1) TN2009000213A1 (fr)
TW (1) TW200831075A (fr)
WO (1) WO2008070011A2 (fr)
ZA (1) ZA200903041B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150437A (en) 2008-03-26 2014-01-30 Novartis Ag Hydroxamate-based inhibitors of deacetylases b
JP2011528662A (ja) * 2008-07-18 2011-11-24 ノバルティス アーゲー ホジキン病の治療のためのｈｄａｃ阻害剤の使用
WO2010009285A1 (fr) * 2008-07-18 2010-01-21 Novartis Ag Utilisation d'inhibiteurs de hdac pour le traitement d'une leucémie myéloïde aiguë et/ou d'un syndrome myélodysplasique
US20110053925A1 (en) * 2009-08-28 2011-03-03 Novartis Ag Hydroxamate-Based Inhibitors of Deacetylases
NZ707377A (en) * 2010-06-07 2015-09-25 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
KR20130101519A (ko) * 2010-09-01 2013-09-13 노파르티스 아게 Ｈｄａｃ 억제제와 혈소판감소증 약물의 조합물
EP2968282B1 (fr) 2013-03-12 2018-05-09 Celgene Quanticel Research, Inc. Inhibiteurs d'histone déméthylase
JP2016538310A (ja) * 2013-11-27 2016-12-08 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法
US9758517B2 (en) 2014-09-17 2017-09-12 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3932914A1 (fr) 2015-03-13 2022-01-05 Valo Health, Inc. Composés alpha-cinnamidiques et compositions comme inhibiteurs de hdac8
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
MXPA05012464A (es) * 2003-05-21 2006-01-30 Novartis Ag Combinacion de inhibidores de deacetilasa de histona con agentes quimioterapeuticos.

Also Published As

Publication number Publication date
WO2008070011A3 (fr) 2008-07-24
IL198638A (en) 2015-06-30
US8093220B2 (en) 2012-01-10
ECSP099483A (es) 2009-08-28
MY148893A (en) 2013-06-14
AR064072A1 (es) 2009-03-11
GT200900148A (es) 2011-08-02
HK1132462A1 (zh) 2010-02-26
US20100069318A1 (en) 2010-03-18
KR101475538B1 (ko) 2014-12-22
EP2099451B1 (fr) 2016-02-10
CL2007003467A1 (es) 2008-07-11
JP5784274B2 (ja) 2015-09-24
JP2014097992A (ja) 2014-05-29
NO20092473L (no) 2009-09-01
AU2007328281A1 (en) 2008-06-12
MA30982B1 (fr) 2009-12-01
CA2670741A1 (fr) 2008-06-12
AU2007328281B2 (en) 2011-03-31
BRPI0719746A2 (pt) 2013-12-10
IL198638A0 (en) 2010-02-17
RU2469717C2 (ru) 2012-12-20
ES2569477T3 (es) 2016-05-11
KR20090087115A (ko) 2009-08-14
TW200831075A (en) 2008-08-01
CA2670741C (fr) 2016-04-12
WO2008070011A2 (fr) 2008-06-12
EP2099451A2 (fr) 2009-09-16
JP2010511702A (ja) 2010-04-15
JP2016006070A (ja) 2016-01-14
MX2009005946A (es) 2009-06-17
RU2009125439A (ru) 2011-01-20
CN101553223A (zh) 2009-10-07
ZA200903041B (en) 2010-03-31
PL2099451T3 (pl) 2016-07-29
PE20081303A1 (es) 2008-10-28

Similar Documents

Publication Publication Date Title
TN2009000213A1 (en) Combination
IL291175A (en) Compositions and methods for treating collagen-mediated diseases
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
EP4371560A3 (fr) Composition pharmaceutique, forme pharmaceutique, procédé pour leur préparation, méthodes de traitement et utilisations de celle-ci
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
WO2013071056A3 (fr) Polythérapie médicamenteuse pour le traitement de tumeurs solides
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
AU2003205768A1 (en) Methods and compositions for treating hyperproliferative conditions
WO2009062576A3 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
WO2006133707A3 (fr) Polytherapie contre le cancer et kit de composants associe
GB201014391D0 (en) Drug composition and its use in therapy
BRPI0507482A (pt) combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.
WO2009075838A3 (fr) Traitement de la ménorragie avec un inhibiteur de l'aromatase
UA104144C2 (ru) Комбинация антагониста с-мет и аминогетероарила для лечения рака
WO2009015447A3 (fr) Nouvelle stratégie immunothérapeutique
TNSN08062A1 (en) Microparticle compositions of the topoisomerase i inhibitor 7-tert-butoxyiminomethylcamptothecin
TN2010000611A1 (en) Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
NZ590332A (en) Combination of antibody 224G11 and PF-2341066 for the treatment of cancer
HK1172550A1 (zh) 利用紫杉烷和刺蝟抑制劑的納米顆粒組合物的聯合治療
HK1125400A (en) Compositions and methods for treating collagen-mediated diseases
HK1169328A1 (en) Method of treating cancer with dll4 antagonist and chemotherapeutic agent